Listen
GONADOTROPHINE CHORIONIQUE ENDO (chorionic gonadotropin), ovulation induction
ENDOCRINOLOGY - FOCUS
Opinions on drugs -
Posted on
Jul 17 2015
Reason for request
Renewal of inclusion
Insufficient clinical benefit in cryptorchidism in the absence of anatomical obstruction
Continued clinical benefit in the treatment or investigation of sterility
- GONADOTROPHINE CHORIONIQUE ENDOhas Marketing Authorisation in the treatment of infertility in combination with FSH or hMG in women (stimulation of ovulation induction) and in men (inadequate deficient spermatogenesis in due to hypogonadotropic hypogonadism), in for the treatment of cryptorchidism in the absence of anatomical obstruction and in for the investigation of Leydig cell function investigations.
- Because of its lower success rate compared to surgical treatment, adverse effects (e.g. temporary virilisation) and its possible long-term consequences on spermatogenesis, treatment with chorionic gonadotropin has no longer a role in the therapeutic strategy for cryptorchidism. Surgical treatment (orchiopexy) is considered as the standard of care.
- In the other indications, the new efficacy and safety data are unlikely to affect the role of this medicinal product in the therapeutic and diagnostic strategy.
Clinical Benefit
| Substantial |
- |
| Insufficient |
Therapeutic use
|
- |
Documents
English version
Contact Us
Évaluation des médicaments
